Pasithea shareholders approve reverse split authorization (1:2–1:20) and 1.75M share increase for equity plan

Pasithea Therapeutics Corp.

• Stockholders approved reverse stock split of common stock at ratio from 1:2 to 1:20, at Board discretion, valid through September 2026.
• Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares by 1.75M to 2,014,221 shares.
• Ratified CBIZ CPAs P.C. as independent auditor for FY2025 with 3.40M for, 39K against, 52K abstain.
• Re-elected Alfred Novak (1.31M for) and Simon Dumesnil (1.29M for) as Class II directors, terms expiring 2028.
• Quorum of 3.5M of 7.4M outstanding shares represented at the meeting; no other business.